Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04061512
Title Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London

Waldenstroem's macroglobulinemia


Cyclophosphamide + Dexamethasone + Rituximab

Ibrutinib + Rituximab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.